Sorafenib has been established as the standard of care for patients with advanced hepatocellular carcinoma (HCC) since 2007 on the basis of two landmark trials (SHARP and Asia-Pacific). Ten years have passed since then and, despite much research in the field, still no validated real-life prognostic markers are available for HCC patients treated with this drug. Therefore, going through 10 years of research into sorafenib of several Italian Cancer Centers, we conducted a field-practice study aimed at identifying baseline clinical factors that could be significantly associated with overall survival (OS).

Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience / Rovesti, Giulia; Orsi, Giulia; Kalliopi, Andrikou; Vivaldi, Caterina; Marisi, Giorgia; Faloppi, Luca; Foschi, Francesco Giuseppe; Silvestris, Nicola; Pecora, Irene; Aprile, Giuseppe; Molinaro, Eleonora; Riggi, Laura; Ulivi, Paola; Canale, Matteo; Cucchetti, Alessandro; Tamburini, Emiliano; Ercolani, Giorgio; Fornaro, Lorenzo; Andreone, Pietro; Zavattari, Patrizia; Scartozzi, Mario; Cascinu, Stefano; Casadei-Gardini, Andrea. - In: GASTROINTESTINAL TUMORS. - ISSN 2296-3774. - 6:3-4(2019), pp. 92-107-107. [10.1159/000502714]

Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience

Rovesti, Giulia;Andreone, Pietro;Casadei-Gardini, Andrea
2019

Abstract

Sorafenib has been established as the standard of care for patients with advanced hepatocellular carcinoma (HCC) since 2007 on the basis of two landmark trials (SHARP and Asia-Pacific). Ten years have passed since then and, despite much research in the field, still no validated real-life prognostic markers are available for HCC patients treated with this drug. Therefore, going through 10 years of research into sorafenib of several Italian Cancer Centers, we conducted a field-practice study aimed at identifying baseline clinical factors that could be significantly associated with overall survival (OS).
6
3-4
92-107
107
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience / Rovesti, Giulia; Orsi, Giulia; Kalliopi, Andrikou; Vivaldi, Caterina; Marisi, Giorgia; Faloppi, Luca; Foschi, Francesco Giuseppe; Silvestris, Nicola; Pecora, Irene; Aprile, Giuseppe; Molinaro, Eleonora; Riggi, Laura; Ulivi, Paola; Canale, Matteo; Cucchetti, Alessandro; Tamburini, Emiliano; Ercolani, Giorgio; Fornaro, Lorenzo; Andreone, Pietro; Zavattari, Patrizia; Scartozzi, Mario; Cascinu, Stefano; Casadei-Gardini, Andrea. - In: GASTROINTESTINAL TUMORS. - ISSN 2296-3774. - 6:3-4(2019), pp. 92-107-107. [10.1159/000502714]
Rovesti, Giulia; Orsi, Giulia; Kalliopi, Andrikou; Vivaldi, Caterina; Marisi, Giorgia; Faloppi, Luca; Foschi, Francesco Giuseppe; Silvestris, Nicola; Pecora, Irene; Aprile, Giuseppe; Molinaro, Eleonora; Riggi, Laura; Ulivi, Paola; Canale, Matteo; Cucchetti, Alessandro; Tamburini, Emiliano; Ercolani, Giorgio; Fornaro, Lorenzo; Andreone, Pietro; Zavattari, Patrizia; Scartozzi, Mario; Cascinu, Stefano; Casadei-Gardini, Andrea
File in questo prodotto:
File Dimensione Formato  
502714.pdf

non disponibili

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 805.11 kB
Formato Adobe PDF
805.11 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1228730
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 20
social impact